BTK and B-cell chronic lymphocytic leukemia: Given the importance of B-cell-receptor signaling in CLL and the central role of Bruton’s tyrosine kinase (BTK) in this pathway, targeted therapy with kinase inhibitors has become an alternative to conventional therapy for CLL [9,10,11].